We also examined FLT3-overexpressing cells following treatment with venetoclax, a potent and highly-selective BCL2 inhibitor clinically active in patients with relapsed/refractory ETP-ALL [51–53]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.